Review



proteome profiler human cytokine array kit 9  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems proteome profiler human cytokine array kit 9
    Proteome Profiler Human Cytokine Array Kit 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 553 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/proteome+profiler+human+cytokine+array+kit+9/Proteome+Profiler+Human+Cytokine+Array+Kit/pm41906686-119-7-14
    Average 96 stars, based on 553 article reviews
    proteome profiler human cytokine array kit 9 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Altered neutrophil signalling linked to impaired chemotaxis and increased ROS and NET production in older people with frailty.
    Article Snippet: Serum cytokine levels were quantified using the Proteome Profiler Human Cytokine Array Kit 9 (R&D systems) following manufacturer’s protocol.



    Similar Products

    96
    R&D Systems proteome profiler human cytokine array kit 9
    Proteome Profiler Human Cytokine Array Kit 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/proteome+profiler+human+cytokine+array+kit+9/Proteome+Profiler+Human+Cytokine+Array+Kit/pm41906686-119-7-14
    Average 96 stars, based on 1 article reviews
    proteome profiler human cytokine array kit 9 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    RayBiotech inc proteome profiler human xl cytokine array kit
    Recruitment of RGS5 + MYL9 + CAFs by DTP cells via CCL11 secretion. A and B, <t>Cytokine</t> arrays and table display changes in cytokine levels from HCC827 cells cultured with various CAF subsets. C, ELISA results reveal concentrations of IL1α, IL13, IL15, MCP-1, MCP-2, CCL11, and GDNF present in the media from HCC827 cells cocultured with different CAF subsets. D, ELISA analysis shows levels of IL13 and CCL11 in media from HCC827 cells cultured with RGS5 + MYL9 + CAFs under vehicle or mitoTEMPO treatment conditions. E, Relative cell viability data for RGS5 + MYL9 + CAFs cocultured with HCC827 cells treated with either vehicle or mitoTEMPO. Osi, osimertinib. F, Schematic overview outlines the migration assay for RGS5 + MYL9 + CAFs. G, Representative images and quantification demonstrate the migration of RGS5 + MYL9 + CAFs toward cocultured HCC827 cells. H, Schematic overview depicts the migration assay for HCC827 cells alongside representative images and quantification of their movement toward cocultured RGS5 + MYL9 + CAFs. I and J, Representative images showing cocultures of RFP-labeled HCC827 cells with GFP-labeled CAFs. Scale bar, 50 μm. K–P, Both HCC827 and RGS5 + MYL9 + CAFs were xenografted into mice treated with osimertinib (5 mg/kg/day) or αCCL11 (2 mg/kg/day). L, Tumor volumes for xenografted mice. M, Body weight of tumors from xenografted mice. N, Percentage survival rate for mice bearing xenografts derived from HCC827 and RGS5 + MYL9 + CAFs. The tick marks in the Kaplan–Meier curves denote censored events corresponding to predefined humane endpoints. These include tumor volume reaching or exceeding 2,000 mm 3 (as measured by caliper) or a loss of body weight greater than 20% from baseline. O, Histologic examinations, including H&E and Ki67 staining, are conducted on tumor tissues from xenograft mice. Scale bar, 100 μm. P, Representative images illustrate TUNEL staining alongside infiltration patterns of RGS5 + MYL9 + CAFs in tumors from xenograft models. Scale bar, 100 μm. The primary CAF subsets utilized in this figure were isolated from patients 07 to 09. Relevant clinical characteristics of these patients are summarized in Supplementary Table S1. Data are presented as the mean ± SD. D and E, Data were analyzed via independent sample t tests; G and M , data were analyzed using one-way ANOVA followed by Dunnett test; N , data were evaluated using a two-sided log-rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Proteome Profiler Human Xl Cytokine Array Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/proteome+profiler+human+cytokine+array+kit+9/Human+Cytokine+Array+Q9/pmc13055635-106-9-16
    Average 95 stars, based on 1 article reviews
    proteome profiler human xl cytokine array kit - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Recruitment of RGS5 + MYL9 + CAFs by DTP cells via CCL11 secretion. A and B, Cytokine arrays and table display changes in cytokine levels from HCC827 cells cultured with various CAF subsets. C, ELISA results reveal concentrations of IL1α, IL13, IL15, MCP-1, MCP-2, CCL11, and GDNF present in the media from HCC827 cells cocultured with different CAF subsets. D, ELISA analysis shows levels of IL13 and CCL11 in media from HCC827 cells cultured with RGS5 + MYL9 + CAFs under vehicle or mitoTEMPO treatment conditions. E, Relative cell viability data for RGS5 + MYL9 + CAFs cocultured with HCC827 cells treated with either vehicle or mitoTEMPO. Osi, osimertinib. F, Schematic overview outlines the migration assay for RGS5 + MYL9 + CAFs. G, Representative images and quantification demonstrate the migration of RGS5 + MYL9 + CAFs toward cocultured HCC827 cells. H, Schematic overview depicts the migration assay for HCC827 cells alongside representative images and quantification of their movement toward cocultured RGS5 + MYL9 + CAFs. I and J, Representative images showing cocultures of RFP-labeled HCC827 cells with GFP-labeled CAFs. Scale bar, 50 μm. K–P, Both HCC827 and RGS5 + MYL9 + CAFs were xenografted into mice treated with osimertinib (5 mg/kg/day) or αCCL11 (2 mg/kg/day). L, Tumor volumes for xenografted mice. M, Body weight of tumors from xenografted mice. N, Percentage survival rate for mice bearing xenografts derived from HCC827 and RGS5 + MYL9 + CAFs. The tick marks in the Kaplan–Meier curves denote censored events corresponding to predefined humane endpoints. These include tumor volume reaching or exceeding 2,000 mm 3 (as measured by caliper) or a loss of body weight greater than 20% from baseline. O, Histologic examinations, including H&E and Ki67 staining, are conducted on tumor tissues from xenograft mice. Scale bar, 100 μm. P, Representative images illustrate TUNEL staining alongside infiltration patterns of RGS5 + MYL9 + CAFs in tumors from xenograft models. Scale bar, 100 μm. The primary CAF subsets utilized in this figure were isolated from patients 07 to 09. Relevant clinical characteristics of these patients are summarized in Supplementary Table S1. Data are presented as the mean ± SD. D and E, Data were analyzed via independent sample t tests; G and M , data were analyzed using one-way ANOVA followed by Dunnett test; N , data were evaluated using a two-sided log-rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

    Journal: Cancer Research

    Article Title: Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR -Mutant Lung Cancer

    doi: 10.1158/0008-5472.CAN-25-0433

    Figure Lengend Snippet: Recruitment of RGS5 + MYL9 + CAFs by DTP cells via CCL11 secretion. A and B, Cytokine arrays and table display changes in cytokine levels from HCC827 cells cultured with various CAF subsets. C, ELISA results reveal concentrations of IL1α, IL13, IL15, MCP-1, MCP-2, CCL11, and GDNF present in the media from HCC827 cells cocultured with different CAF subsets. D, ELISA analysis shows levels of IL13 and CCL11 in media from HCC827 cells cultured with RGS5 + MYL9 + CAFs under vehicle or mitoTEMPO treatment conditions. E, Relative cell viability data for RGS5 + MYL9 + CAFs cocultured with HCC827 cells treated with either vehicle or mitoTEMPO. Osi, osimertinib. F, Schematic overview outlines the migration assay for RGS5 + MYL9 + CAFs. G, Representative images and quantification demonstrate the migration of RGS5 + MYL9 + CAFs toward cocultured HCC827 cells. H, Schematic overview depicts the migration assay for HCC827 cells alongside representative images and quantification of their movement toward cocultured RGS5 + MYL9 + CAFs. I and J, Representative images showing cocultures of RFP-labeled HCC827 cells with GFP-labeled CAFs. Scale bar, 50 μm. K–P, Both HCC827 and RGS5 + MYL9 + CAFs were xenografted into mice treated with osimertinib (5 mg/kg/day) or αCCL11 (2 mg/kg/day). L, Tumor volumes for xenografted mice. M, Body weight of tumors from xenografted mice. N, Percentage survival rate for mice bearing xenografts derived from HCC827 and RGS5 + MYL9 + CAFs. The tick marks in the Kaplan–Meier curves denote censored events corresponding to predefined humane endpoints. These include tumor volume reaching or exceeding 2,000 mm 3 (as measured by caliper) or a loss of body weight greater than 20% from baseline. O, Histologic examinations, including H&E and Ki67 staining, are conducted on tumor tissues from xenograft mice. Scale bar, 100 μm. P, Representative images illustrate TUNEL staining alongside infiltration patterns of RGS5 + MYL9 + CAFs in tumors from xenograft models. Scale bar, 100 μm. The primary CAF subsets utilized in this figure were isolated from patients 07 to 09. Relevant clinical characteristics of these patients are summarized in Supplementary Table S1. Data are presented as the mean ± SD. D and E, Data were analyzed via independent sample t tests; G and M , data were analyzed using one-way ANOVA followed by Dunnett test; N , data were evaluated using a two-sided log-rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

    Article Snippet: Cytokine profiles from LUAD cells were analyzed using the Proteome Profiler Human XL Cytokine Array Kit (RayBio).

    Techniques: Cell Culture, Enzyme-linked Immunosorbent Assay, Migration, Labeling, Derivative Assay, Staining, TUNEL Assay, Isolation